Hemorrhagic StrokeNCT05121415
Investigation of Genetic Disease Marker Associated With Spontaneous Haemorrhagic Stroke Complicating Severe Pre-eclampsia in Pregnancy
An observational study of Hemorrhagic Stroke and Eclampsia, run by Asfendiyarov Kazakh National Medical University at 1 site in Kazakhstan.
Trial summary
To search for a genetic marker of hemorrhagic stroke complicating severe eclampsia, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with hemorrhagic stroke and normal control will be performed. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Hemorrhagic Stroke, Eclampsia
- What is being tested?
- SNP analysis of the DNA
- How many people
- 100 participants
- Where
- 1 siteKazakhstan
- Study dates
- 23 Oct 2021to 20 Jan 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- Adult
Study population: patients with hemorrhagic stroke complicating severe eclampsia in pregnancy who visited Scientific Center for Obstetrics, Gynecology and Perinatology. Kazakhstan, Almaty
Who may be able to join
- -patients with hemorrhagic stroke complicating severe eclampsia in pregnancy
Who cannot join
- patients without hemorrhagic stroke complicating severe eclampsia in pregnancy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Preventive and Personalized Medicine (2021-2023)
To search for a genetic marker of hemorrhagic stroke complicating severe eclampsia, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with hemorrhagic stroke and normal control will be performed.
Read the detailed description
Detailed Description:
Unrelated Korean subjects who have Spontaneous hemorrhagic stroke complicating severe eclampsia in pregnancy were recruited in the current study. Genotyping for various SNP associated due to the linkage disequilibrium patterns is to be performed. Genotypes would be statistically compared between patients with hemorrhagic stroke and normal control subjects free of hemorrhagic stroke
- Conditions
- Hemorrhagic Stroke, Eclampsia
- Being tested
- SNP analysis of the DNA
- Keywords
- SNP
- Medical subject headings
- Hemorrhagic Stroke, Eclampsia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SNP analysis of the DNAGenetic
SNP analysis of the DNA obtained from peripheral blood sample
| Study group | Role | What they receive |
|---|---|---|
| Experimental group: | patients with hemorrhagic stroke complicating severe pre-eclampsia in pregnancy Receives: Genetic: SNP analysis of the DNA | |
| Control group | patients without hemorrhagic stroke complicating severe pre-eclampsia in pregnancy Receives: Genetic: SNP analysis of the DNA |
What is being measured
The primary outcome is the main question the study is designed to answer.
genotyping for the SNP associated with hemorrhagic stroke complicating severe eclampsia in pregnancy
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Nov 2021
- Study start23 Oct 2021
- Primary completion20 Jan 2023
- Study completion20 Jan 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hemorrhagic StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Asfendiyarov Kazakh National Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ildar Fakhradiyev, Asfendiyarov Kazakh National Medical University
- Investigators
- Aygul Terlikbayeva, PhD, Study director, JSC "Scientific center of obstetrics, gynecology and perinatology"
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05121415
- Sponsor's protocol ID
- 1189
- Status last verified
- Mar 2023
- First submitted
- 21 Oct 2021
- Last updated
- 14 Mar 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 14 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Preventive and Personalized Medicine (2021-2023)
- ClinicalTrials.gov ID
- NCT05121415
- Acronym / sponsor ID
- 1189
- Conditions
- Hemorrhagic Stroke, Eclampsia
- Keywords
- SNP
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Asfendiyarov Kazakh National Medical UniversityUniversity, hospital or other
- Study start
- 23 Oct 2021 (actual)
- Primary completion
- 20 Jan 2023 (actual)
- Study completion
- 20 Jan 2023 (actual)
- First posted
- 16 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To search for a genetic marker of hemorrhagic stroke complicating severe eclampsia, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with hemorrhagic stroke and normal control will be performed.
Detailed description
Detailed Description:
Unrelated Korean subjects who have Spontaneous hemorrhagic stroke complicating severe eclampsia in pregnancy were recruited in the current study. Genotyping for various SNP associated due to the linkage disequilibrium patterns is to be performed. Genotypes would be statistically compared between patients with hemorrhagic stroke and normal control subjects free of hemorrhagic stroke
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental group: | – | Genetic: SNP analysis of the DNApatients with hemorrhagic stroke complicating severe pre-eclampsia in pregnancy |
| Control group | – | Genetic: SNP analysis of the DNApatients without hemorrhagic stroke complicating severe pre-eclampsia in pregnancy |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Age groups
- Adult
- Study population
- patients with hemorrhagic stroke complicating severe eclampsia in pregnancy who visited Scientific Center for Obstetrics, Gynecology and Perinatology. Kazakhstan, Almaty
Key inclusion criteria (1 listed)
- -patients with hemorrhagic stroke complicating severe eclampsia in pregnancy
Key exclusion criteria (1 listed)
- patients without hemorrhagic stroke complicating severe eclampsia in pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SNP analysis of the DNASNP analysis of the DNA obtained from peripheral blood sample | Genetic | Control group, Experimental group: |
Primary outcome
genotyping for the SNP associated with hemorrhagic stroke complicating severe eclampsia in pregnancy
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Mar 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Hemorrhagic Stroke
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Recruiting
Hand and Arm Motor Recovery Via Non-invasive Electrical Spinal Cord Stimulation After Stroke
Stroke, Ischemic, Chronic Stroke
RecruitingPhase 3
Thrombolysis in Factor Xa-inhibitors Trial
Stroke, Stroke (in Patients With Atrial Fibrillation)
Not yet recruitingObservational study
Detecting and Predicting Post-stroke Cognitive Impairment Using the Oxford Cognitive Screen
Stroke, Ischemic Stroke
Not yet recruiting
Accelerated Theta-Burst Stimulation for Refractory Central Post-Stroke Pain
Central Post-Stroke Pain, Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Aygul Terlikbayeva, PhD study director
JSC "Scientific center of obstetrics, gynecology and perinatology"
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hemorrhagic Stroke and Eclampsia, run by Asfendiyarov Kazakh National Medical University at 1 site in Kazakhstan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Kazakhstan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
genotyping for the SNP associated with hemorrhagic stroke complicating severe eclampsia in pregnancy (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Mar 2023; AzTrials last refreshed its copy on 8 Nov 2026.